The estimated Net Worth of Angus C. Russell is at least $569 Tausend dollars as of 18 August 2022. Mr. Russell owns over 1,984 units of Mallinckrodt Plc stock worth over $1,969 and over the last 11 years he sold MNK stock worth over $0. In addition, he makes $567,000 as Independent Non-Executive Chairman of the Board at Mallinckrodt Plc.
Sign up
Mr. Russell MNK stock SEC Form 4 insiders trading
Angus has made over 13 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,984 units of MNK stock worth $675 on 18 August 2022.
The largest trade he's ever made was exercising 96,864 units of Mallinckrodt Plc stock on 10 August 2021 worth over $32,934. On average, Angus trades about 5,734 units every 41 days since 2014. As of 18 August 2022 he still owns at least 5,792 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. Russell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Angus Russell biography
Angus Charles Russell Ph.D. is an Independent Non-Executive Chairman of the Board of the Company. Mr. Russell has been Chairman of the Board since May 2018, and a director since August 2014. He is also a member of Mallinckrodt’s Portfolio Committee and its Audit Committee. Mr. Russell served as a director of Questcor Pharmaceuticals, Inc. from June 2013 until Questcor was acquired by us in August 2014. Mr. Russell served as Chief Executive Officer of Shire Plc, a leading global specialty biopharmaceutical company, from 2008 until his retirement in April 2013 and was a member of its Board of Directors from 1999 to 2013. From 1999 to 2008, Mr. Russell served as Chief Financial Officer of Shire. Prior to joining Shire, Mr. Russell served at ICI, Zeneca and AstraZeneca, most recently as VP of Corporate Finance at AstraZeneca. Mr. Russell has served as the non-executive Chairman of Revance Therapeutics, Inc. since March 2014. He has served as a director of BioTime, Inc. since December 2014 and as a director of Therapeutics MD, Inc. since March 2015. He was a director of InterMune, Inc. from 2011 to 2014. Mr. Russell is a Chartered Accountant.
What is the salary of Angus Russell?
As the Independent Non-Executive Chairman of the Board of Mallinckrodt Plc, the total compensation of Angus Russell at Mallinckrodt Plc is $567,000. There are 6 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
How old is Angus Russell?
Angus Russell is 64, he's been the Independent Non-Executive Chairman of the Board of Mallinckrodt Plc since 2018. There are 2 older and 9 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
What's Angus Russell's mailing address?
Angus's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.
Insiders trading at Mallinckrodt Plc
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... und Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
What does Mallinckrodt Plc do?
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
What does Mallinckrodt Plc's logo look like?
Complete history of Mr. Russell stock trades at Revance Therapeutics Inc, Mallinckrodt Plc, TherapeuticsMD, TherapeuticsMD Inc und Lineage Cell Therapeutics Inc
Mallinckrodt Plc executives and stock owners
Mallinckrodt Plc executives and other stock owners filed with the SEC include:
-
Mark Trudeau,
President, Chief Executive Officer, Director -
Steven Romano,
Executive Vice President, Chief Scientific Officer -
Hugh O'Neill,
Executive Vice President, Chief Commercial Officer -
Mark Casey,
Executive Vice President and Chief Legal Officer -
Bryan Reasons,
Chief Financial Officer, Executive Vice President -
Ian Watkins,
Chief Human Resource Officer, Executive Vice President -
Angus Russell,
Independent Non-Executive Chairman of the Board -
JoAnn Reed,
Independent Director -
J. Martin Carroll,
Independent Director -
David Norton,
Independent Director -
Kneeland Youngblood,
Independent Director -
Anne Whitaker,
Independent Director -
Paul Carter,
Independent Director -
Carlos Paya,
Independent Director -
Daniel Speciale,
Vice President - Investor Relations and IRO -
David R Carlucci,
Director -
Virgil D Thompson,
Director -
Diane H. Gulyas,
Director -
Matthew K Harbaugh,
SVP&Chief Financial Officer -
Michael Bryant Hicks,
Sr. VP & General Counsel -
Ronald K. Lloyd,
Sr. VP & Pres, Hospital -
Raymond J. Furey,
SVP & Chief Compliance Officer -
Gary M. Phillips,
Sr. VP & Chief Strategy Ofcr. -
Meredith B Fischer,
SVP, Communic. & Public Affair -
Melvin D Booth,
Director -
Joseph A Zaccagnino,
Director -
Coleman N Iii Lannum,
VP, Investor Relations -
Dagmar Rosa Bjorkeson,
Chief Strat & Corp Dev Officer -
Sigurdur O Olafsson,
President and CEO -
Kassie Harrold,
Chief Compliance Officer -
Jason Daniel Goodson,
EVP & Head of Corp Development -
Henriette Nielsen,
EVP & Chief Transformation OFC -
Lisa French,
EVP & Chief Commercial Officer -
Mark Anthony Tyndall,
EVP & Chief Legal Offi & Secre -
Stephen Andrew Welch,
EVP & Head of Spec Generics -
Frank Scholz,
SVP, Global Operations -
George A. Kegler,
EVP & CFO, Interim -
Karen Patruno Sheehy,
Sr. VP & Chief Compliance Off. -
James E Deerfield Mgmt L.P....,
-
Don M Bailey,
Director -
Sandra L Hatten,
Sr. Vice President Quality -
Terrance L Carlson,
Interim General Counsel -
& Co. Inc. Paulson,
10% owner -
Holding Ltd Enceladus,
-
Thomas E Berry,
See Remarks -
Peter G Edwards,
See Remarks -
Stefano R Carchedi,
See Remarks -
Stephen Merrick,
See Remarks -
Nancy Lurker,
Director -
Mario D. Saltarelli,
Sr. VP & Chief Science Ofcr. -
Kathy A Schaefer,
Sr. VP Fin & Corp. Controller -
Peter C Richardson,
EVP & Chief Scientific Officer -
Daniel Arthur Celentano,
Director -
Woodrow A Jr Myers,
Director -
Paul Bisaro,
Director -
James R Sulat,
Director -
Susan Michele Silbermann,
Director -
Karen Ling,
Director -
Neal P Goldman,
Director -
Riad Hussein El Dada,
Director